Casdin Capital’s Editas Medicine EDIT Stock Holding History

Casdin Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-415,000	Closed	-$9.44M	–	33
2019 Q3	$9.44M	Sell	415,000 -65,000	-14%	-$1.61M	0.98%	27
2019 Q2	$11.9M	Hold	480,000	–	–	1.11%	24
2019 Q1	$11.7M	Hold	480,000	–	–	1.29%	21
2018 Q4	$10.9M	Buy	480,000 +20,000	+4%	+$544K	1.87%	22
2018 Q3	$14.6M	Buy	460,000 +281,667	+158%	+$9.1M	1.78%	21
2018 Q2	$6.39M	Buy	178,333 +45,000	+34%	+$1.59M	0.89%	25
2018 Q1	$4.42M	Hold	133,333	–	–	0.78%	25
2017 Q4	$4.1M	Hold	133,333	–	–	1%	21
2017 Q3	$3.2M	Hold	133,333	–	–	0.9%	24
2017 Q2	$2.24M	Hold	133,333	–	–	0.83%	30
2017 Q1	$2.98M	Buy	133,333 +68,333	+105%	+$1.42M	1.76%	21
2016 Q4	$1.05M	Sell	65,000 -20,470	-24%	-$311K	0.87%	24
2016 Q3	$1.15M	Buy	+85,470	New	+$1.75M	0.93%	25
2016 Q2	–	Sell	-85,470	Closed	-$2.95M	–	29
2016 Q1	$2.95M	Buy	+85,470	New	+$2.25M	3.39%	14

Other funds holding EDIT

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Casdin Capital's EDIT Position: Q4 2019 in Review

Casdin Capital sold out of Editas Medicine (EDIT) in Q4 2019, closing a stake of 415,000 shares — an estimated $9.44M sold.

Casdin Capital first reported a position in EDIT in Q1 2016 and held it in 14 quarters. The position peaked at $14.6M in Q3 2018. 229 funds tracked by Wall St. Rank hold EDIT as of Q4 2019.

Casdin Capital reported no remaining Editas Medicine position as of Q4 2019 after selling out during the quarter.
Casdin Capital sold 415,000 Editas Medicine shares in Q4 2019, an estimated $9.44M.
Casdin Capital first reported a position in Editas Medicine in Q1 2016 and held it in 14 quarters.
Casdin Capital's Editas Medicine position peaked at $14.6M in Q3 2018.
229 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2019.

Based on Casdin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.